enGene FY2026 EPS Estimate Lowered by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN) – Leerink Partnrs lowered their FY2026 earnings per share estimates for shares of enGene in a research report issued on Tuesday, November 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($2.14) for the year, down from their previous estimate of ($2.05). The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for enGene’s FY2027 earnings at ($2.42) EPS, FY2028 earnings at ($1.70) EPS and FY2029 earnings at ($0.24) EPS.

A number of other brokerages have also commented on ENGN. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of enGene in a research note on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. UBS Group upped their price target on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday. Raymond James Financial raised enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price target on the stock in a report on Tuesday. Finally, Morgan Stanley upped their target price on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.38.

enGene Stock Up 6.4%

Shares of NASDAQ ENGN traded up $0.54 during mid-day trading on Friday, reaching $8.97. 565,603 shares of the company’s stock traded hands, compared to its average volume of 399,900. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The business has a 50-day simple moving average of $7.27 and a 200 day simple moving average of $4.97. The stock has a market cap of $459.23 million, a P/E ratio of -4.75 and a beta of -0.27. enGene has a 1-year low of $2.65 and a 1-year high of $11.14.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06).

Institutional Trading of enGene

A number of hedge funds have recently modified their holdings of ENGN. PFS Partners LLC bought a new position in shares of enGene in the 3rd quarter worth about $61,000. Paloma Partners Management Co bought a new position in shares of enGene during the second quarter valued at approximately $38,000. Affinity Asset Advisors LLC purchased a new position in shares of enGene during the second quarter valued at approximately $280,000. Cresset Asset Management LLC bought a new stake in shares of enGene in the 2nd quarter worth approximately $36,000. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after buying an additional 41,874 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.